The Newest Patient May Be At The Greatest Risk.
Newborns are highly vulnerable to infection. As respiration and other functions of the organs is passed to the infant the baby’s risk is extremely high. Neonatal pneumonia is a common result of neonatal infection and is responsible for many infant deaths within the first month. And, unless the newborn requires incubation for suspected disease or illness, the baby is generally not isolated. This is where an Airocide® bioconversion system can make a big difference.
In clinical studies supported by peer reviewed papers, Airocide systems have been shown to eliminate virtually all airborne pathogens, VOCs, mycotoxins, mold spores - regardless of size. Bacteria and viruses that ride in with traffic, are exhaled by an infant or make it past the HVAC filtration system won’t last long in an Airocide environment. Infection can come from airborne bacteria or bacteria commonly found on the skin (staphylococcus epidermis). And while the room may be well protected from outside environmental pathogens, inside is another matter. A neonatal ward filled with unprotected newborns able to infect each other with every new breath, airborne bacteria and viruses are free to have a field day.
Airocide® destroys all airborne organics at a molecular level by converting them into inorganic vapor. No filters are involved. No ozone is either used or generated as a byproduct. And other than replacing the lamp source for the catalyst once a year, no maintenance is required. Top it off with the fact that it consumes no more energy than a light bulb and failure to employ this NASA developed proprietary technology is simply inexcusable.
Airocide systems destroy all airborne organics at a molecular level, converting them into harmless vapor. No filters are involved. No ozone is either used or generated as a byproduct. And other than replacing the UV bulbs once a year, no maintenance is required. Top it off with the fact that it consumes no more energy than a light bulb; failure to employ this proprietary NASA developed technology is simply inexcusable.
CASE STUDY: “Protect the ones whose parents look to you for life...” Advanced Air Sanitization in a Pediatric Setting - A clinical Study of Indoor Air Quality Data... Michael R. Papciak, M.D.
A clinical test of the Airocide® bioconversion system was conducted in a pediatrician’s office complex. The primary objective of the test was to determine the effect on airborne bacteria of turning off an Airocide bioconversion system that had been operating 24/7 for a period of six months inside the pediatric facility. The secondary objective was to measure the difference in performance of the Airocide bioconversion system in a pediatric “sick” waiting room compared to a pediatric “well” waiting room. In 24-hours, after turning off the Airocide® bioconversion system, the airborne bacteria in the facility increased by an average of 181%. One week later the average level of airborne bacteria was 211% higher than when the Airocide bioconversion system was operating.
